gbr-12935

GBR 12935 dihydrochloride (GBR 12935) can induce the increase of the extracellular levels of dopamine to basal levels.

GBR-12935 is a piperazine derivative. It is an effective and selective dopamine reuptake inhibitor. GBR-12935 is now widely used in animal research into Parkinson's disease and the dopamine pathways in the brain.

CM764 is a potent and selective antagonist of sigma-2 receptors, a novel derivative of SN79.

GBR-12935 is a potent and selective dopamine reuptake inhibitor. It was originally developed in its 3H radiolabelled form for the purpose of mapping the distribution of dopaminergic neurons in the brain by selective labelling of dopamine transporter proteins. This has led to potential clinical uses in the diagnosis of Parkinson's disease, although selective radioligands such as Ioflupane (¹²³I) are now available for this application. GBR-12935 is now widely used in animal research into Parkinson's disease and the dopamine pathways in the brain. (Source: http://en.wikipedia.org/wiki/GBR-12935).

SRI-31142 is a proposed brain-penetrant allosteric inhibitor of the dopamine transporter (DAT). In behavioral studies utilizing intracranial self-stimulation (ICSS), SRI-31142 does not produce the abuse-related effects observed with cocaine and GBR-12935. Instead, at effective doses, it reduces ICSS responding and dopamine levels in the nucleus accumbens (NAc). Additionally, SRI-31142 can prevent cocaine-induced increases in ICSS and NAc dopamine.